Posters

Trifocal IOL implantation to correct presbyopia: 4 years of experience and improvements in quality of vision–clinical results

Poster Details

First Author: M. Piovella ITALY

Co Author(s): B. Kusa                    

Abstract Details

Purpose:

To evaluate visual and optical performances of cataract eyes after phacoemulsification and trifocal Intraocular Lens (IOL - AT LISA tri 839MP, Carl Zeiss Meditec) implantation. Evaluation of a new method and different preop organization to improve visual outcomes based on eye selection and not on patients habits.

Setting:

C.M.A. Centro Microchirurgia Ambulatoriale Monza, Italy

Methods:

111 eyes of 67 patients mean age: 67.17 ± 11.46 years underwent uncomplicated phacoemulsification and trifocal IOL (AT LISA tri839MP, Carl Zeiss Meditec) implantation. Preloaded IOL was implanted using a BLUEMIXS 180 injector for a 2.4 corneal incision. Postoperatively, the following visual and refractive parameters were measured: distance (5m) near (40cm) and intermediate (80 cm) visual acuity, corneal topography and aberrometry, contrast sensitivity and defocus curve. Regular follow-up examinations were performed up to 4 years after surgery. Biometry was managed with specific attention in more problematic patients (dry eye ) to obtain similar results in different evaluation time

Results:

Preoperative distance UCVA was 20/125. At 4 years, distance UCVA is 20/20 , monocular and binocular uncorrected near vision and intermediate vision are 20/32. After four year experience with trifocal IOLs ,in year 2015 trifocal technology was applied in 73% of patients that submitted cataract surgery in our surgical center. 94% of eyes achieved post operative refractive results within ± 0.50 diopter (sph equivalent)

Conclusions:

AT LISA tri 839MP provided good distance and near as well as intermediate visual acuity. This lens also improved quality of vision through remarkable diffraction efficiency and less penalization of contrast sensitivity. Patients did not report night time driving difficulties In four years experience we did not explanted any lens. AT LISA tri 839MP is our first choice IOL to correct presbyopia in cataract patients because it has replaced bifocal Iols

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented